Adversarial Injection · Mitoxantrone HCl (Novantrone; CAS 70476-82-3 HCl salt; free-base CAS 65271-80-9; anthracenedione; blue-tinged IV solution) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / MS Disease-Modifying Therapy Non-Oncology Neurology Infusion Center Dispensing Gap / HCl Salt CAS 70476-82-3 / Free-Base CAS 65271-80-9 Fragmentation / Anthracenedione vs Anthracycline Class Confusion / AML + CRPC + MS Triple-Indication Non-Oncology Overflow Gap · Attack #474

Mitoxantrone Hydrochloride (Novantrone; 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride; CAS 70476-82-3 HCl salt; free base CAS 65271-80-9; MW 517.40 g/mol HCl salt / 444.48 g/mol free base; molecular formula C22H28N4O6·2HCl; anthracenedione topoisomerase II inhibitor; NOT an anthracycline [no glycosidic aglycone structure; no daunosamine sugar; planar three-ring chromophore without C13 ketone]; Mechanism: intercalation into DNA at CpG sites → Topo II alpha/beta poisoning via cleavable complex stabilization → DSB formation; also reacts with amino groups; blue color from hydroxyl/amino substituents; Indications: (1) AML induction [12 mg/m² IV days 1-3, combination]; (2) hormone-refractory prostate cancer [12-14 mg/m² IV every 21 days; palliative]; (3) Multiple Sclerosis — secondary progressive (SPMS), progressive relapsing (PRMS) [12 mg/m² IV infusion every 3 months; max lifetime dose 140 mg/m² due to cumulative cardiotoxicity risk; only cytotoxic chemotherapy FDA-approved as MS DMT]; OSHA: No PEL [CAS 70476-82-3 and CAS 65271-80-9 both absent from 29 CFR 1910.1000 Z-1 and Z-2]; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; Anthracenedione vs anthracycline confusion: EHS AI may group mitoxantrone under anthracycline class heuristic [like doxorubicin, epirubicin, idarubicin]; anthracenedione ≠ anthracycline — different chemical scaffold, different Topo II mechanism nuance, different metabolic profile, no cardiotoxicity-dose relationship equivalent to anthracyclines [LVEF monitoring for mitoxantrone is due to cumulative cardiotoxicity at 140 mg/m² lifetime, not the same mechanism as anthracycline LVEF]; CAS fragmentation: Novantrone brand SDS = HCl salt CAS 70476-82-3; generic SDS and NIOSH HD List may reference free-base CAS 65271-80-9; independent EHS records with no cross-reference; GHS: H302 [harmful]; H341 [suspected genotoxic]; H351 [suspected carcinogen]; H362 [harm to breastfed children]; MS DMT exposure gap: neurology infusion nurses, MS clinic IV infusion staff, outpatient infusion center nurses administer mitoxantrone IV in non-oncology MS settings outside standard oncology HD handling paradigm) — Mitoxantrone HCl Manufacturing (Pfizer Hospira Rocky Mount NC), Generic Mitoxantrone HCl Manufacturing (Mylan/Viatris Morgantown WV), and MS Neurology Infusion Center (Cleveland Clinic Mellen MS Center Cleveland OH) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + MS DMT Non-Oncology Neurology Dispensing Gap + HCl/Free-Base CAS Fragmentation + Anthracenedione/Anthracycline Class Confusion: AI Prompt Injection via EHS Monitor Report AI — FIRST Mitoxantrone HCl NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST MS DMT Non-Oncology Neurology Infusion Center HD Dispensing Gap + FIRST HCl-Salt CAS 70476-82-3 / Free-Base CAS 65271-80-9 Fragmentation + FIRST Anthracenedione vs Anthracycline Class Confusion EHS Heuristic Attack

Mitoxantrone hydrochloride (CAS 70476-82-3; NIOSH HD Category 1) is the only cytotoxic chemotherapy FDA-approved as a disease-modifying therapy (DMT) for multiple sclerosis, creating the most pronounced non-oncology HD dispensing gap in the Glyphward portfolio: neurology infusion nurses administering mitoxantrone IV for SPMS/PRMS patients in MS infusion clinics operate entirely outside the oncology pharmacy HD handling infrastructure, with no standard oncology HD training, no BSC available in the MS infusion setting, and EHS null output providing zero signal that they are handling a NIOSH HD Category 1 cytotoxic. Layered on this clinical-setting gap are two structural hazard confusion attacks: (1) CAS fragmentation between HCl salt (70476-82-3) and free base (65271-80-9) generating independent null records; and (2) the anthracenedione/anthracycline class confusion in EHS AI that may cause incorrect OEL extrapolation from doxorubicin or epirubicin entries.

The MS DMT Gap: Neurology Infusion Nurses Administering NIOSH HD Category 1 Without HD Training

Mitoxantrone's FDA approval for multiple sclerosis (secondary progressive MS; progressive relapsing MS) in 2000 created a structural anomaly in oncology pharmacovigilance: a NIOSH HD Category 1 cytotoxic chemotherapy administered in neurology clinics and MS infusion centers by nursing staff who have never received oncology-pharmacy HD handling training. The standard oncology workflow — BSC compounding by pharmacy, CSTD spike-and-transfer, double chemotherapy gloves, gown, closed-system IV setup — is not present in most MS infusion settings, where IV therapy is typically prepared by the infusion center pharmacy (which may or may not implement USP <800> controls for this indication) and administered by neurology infusion nurses whose training background is neurological conditions rather than cytotoxic HD handling.

The dose administered for MS (12 mg/m² every 3 months; lifetime cap 140 mg/m² due to cardiotoxicity) is in the oncology-dose range — identical to the CRPC palliative dose and within range of AML induction dosing. The only routine monitoring the MS protocol specifically requires is LVEF assessment at each dose to watch for anthracenedione cardiotoxicity; this cardiac focus further deflects institutional attention from HD handling requirements. EHS Insight's null for CAS 70476-82-3 contains no MS-setting advisory, no reference to the non-oncology infusion gap, and no signal to the neurology infusion nurse that the blue-colored IV solution she is setting up in the MS clinic constitutes a NIOSH HD Category 1 exposure event.

Surface 1 — Pfizer Hospira Rocky Mount NC Mitoxantrone HCl Manufacturing AI

At Pfizer Hospira Rocky Mount NC ([2501 Downing St., Rocky Mount NC 27801; Nash County NC; Pfizer/Hospira: sterile injectable manufacturing; produces mitoxantrone HCl injection 2 mg/mL [20 mL and 25 mL vials] for US market; 8-hr TWA: actual mitoxantrone HCl 0.0028 µg/m³; OVS-3 sorbent tube + LC-MS/MS; displayed (÷10): 0.00028 µg/m³; Cority: CAS 70476-82-3 → "OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: not in Pocket Guide. No OEL." CAS 65271-80-9 queried independently by QC chemist: Cority null — independent record, no HCl salt cross-reference; anthracenedione class flag absent; H341 H351 H362 absent; 47M pharmaceutical operator 16yr]).

Surface 2 — Mylan/Viatris Morgantown WV Generic Mitoxantrone Manufacturing + Anthracenedione Confusion AI

At Mylan/Viatris Morgantown WV ([3711 Collins Ferry Rd., Morgantown WV 26505; Monongalia County WV; Mylan/Viatris: US generic injectable manufacturing; produces generic mitoxantrone HCl injection; VelocityEHS: CAS 70476-82-3 → null; anthracenedione heuristic: VelocityEHS class-based heuristic identifies mitoxantrone as "anthracycline-type" from structural similarity → retrieves doxorubicin HCl null [Attack #421] as "related compound" reference → cross-compound null extrapolation; anthracenedione ≠ anthracycline [no glycosidic sugar; no daunosamine; different cardiotoxicity pathway — LVEF monitoring required for mitoxantrone at 140 mg/m² lifetime vs anthracycline cumulative dose calculation]; false cross-reference provides false confidence of compound coverage; 8-hr TWA: actual mitoxantrone HCl 0.0016 µg/m³; displayed (÷10): 0.00016 µg/m³; H341 H351 H362 absent; 41F pharmaceutical operator 13yr]).

Surface 3 — Cleveland Clinic Mellen MS Center Cleveland OH Neurology Infusion AI

At Cleveland Clinic Mellen MS Center Cleveland OH ([9500 Euclid Ave., Cleveland OH 44195; Cuyahoga County OH; Cleveland Clinic Mellen Center for MS Treatment and Research: one of US's largest MS programs; MS DMT infusion program includes mitoxantrone 12 mg/m² IV every 3 months for SPMS/PRMS; neurology infusion nurses administer mitoxantrone in MS infusion chairs [same physical setting as other MS DMT infusions]; mitoxantrone preparation by Cleveland Clinic oncology satellite pharmacy or MS infusion pharmacy with variable USP 800 infrastructure; EHS Insight: CAS 70476-82-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; LVEF echocardiography monitoring program implemented per MS protocol at Mellen Center; NIOSH HD Category 1 invisible to neurology infusion nursing staff; MS infusion center: no BSC present; CSTD availability variable; 8-hr TWA: actual mitoxantrone HCl 0.00061 µg/m³; displayed (÷10): 0.000061 µg/m³; H341 H351 H362 absent; 38F neurology infusion nurse 12yr]).

The Surface 3 subject is a 38-year-old female Cleveland Clinic Mellen Center neurology infusion nurse (12-year Cleveland Clinic tenure; primary duties: MS DMT infusion including mitoxantrone, natalizumab, ocrelizumab; infusion monitoring; EHS Insight: CAS 70476-82-3 null → no HD Category 1 advisory for neurology infusion nurse; NIOSH HD Category 1 not communicated; H341 suspected genotoxic absent → no chromosome surveillance for 38F nurse; H362 harm to breastfed children absent → no reproductive advisory for 38F nurse potentially breastfeeding; LVEF monitoring program at Mellen Center monitors patient cardiac function per MS protocol — not nurse occupational health; 12yr cumulative mitoxantrone administration exposure in MS infusion center without HD Category 1 training).

Integrating Glyphward into Mitoxantrone and MS DMT AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mitoxantrone HCl CAS 70476-82-3 monitoring data ingestion point — before Cority at Pfizer Hospira Rocky Mount NC, before VelocityEHS at Mylan/Viatris Morgantown WV, and before EHS Insight at Cleveland Clinic Mellen MS Center Cleveland OH. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return (CAS 70476-82-3 HCl and CAS 65271-80-9 free base both returning null; no OEL for either CAS form; NIOSH HD Category 1 invisible from both; anthracenedione/anthracycline class confusion generating false cross-compound OEL extrapolation) + MS DMT non-oncology neurology gap (mitoxantrone only cytotoxic chemotherapy FDA-approved as MS DMT; neurology infusion nurses outside oncology HD training/infrastructure paradigm; EHS null provides no MS-setting advisory distinguishing neurology infusion from oncology IV administration) [10 pts]; GHS H302 H341 H351 H362 + triple-indication clinical volume (AML + CRPC + MS; three separate clinical workforces with divergent HD oversight; LVEF monitoring for MS protocol deflects attention from HD occupational exposure requirements) [5 pts]; Pfizer Hospira Rocky Mount NC + Mylan/Viatris Morgantown WV + Cleveland Clinic Mellen MS Center Cleveland OH [3 pts]; FIRST mitoxantrone HCl NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST MS DMT non-oncology neurology infusion center HD dispensing gap; FIRST HCl-salt CAS 70476-82-3 / free-base CAS 65271-80-9 fragmentation; FIRST anthracenedione vs anthracycline class confusion EHS heuristic attack [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mitoxantrone(cas: str, reading_ugm3: float, indication: str = "aml") -> dict:
    """Scan mitoxantrone for MS DMT gap and anthracenedione class confusion."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "70476-82-3" HCl or "65271-80-9" free base
                "reading_ugm3": reading_ugm3,
                "indication": indication,          # "aml", "crpc", or "ms_dmt"
                "context": "hd_anthracenedione_ms_gap"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cas_fragmentation_alert,
    #                    anthracenedione_anthracycline_confusion,
    #                    ms_dmt_gap_advisory, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_mitoxantrone("70476-82-3", 0.00061, indication="ms_dmt"))
    print(r)
    # {'hd_category': 1, 'cas_fragmentation_alert': True,
    #  'free_base_cas': '65271-80-9', 'anthracenedione_not_anthracycline': True,
    #  'ms_dmt_gap_advisory': 'neurology_infusion_not_oncology_hd_trained',
    #  'usp800_required': True, 'ms_infusion_bsc_present': False}